Loading…
← CockpitCompetitor Analysis › ONESOURCE.NS OneSource Specialty PharmaOpen in the cockpit ↗

OneSource Specialty PharmaONESOURCE.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.

≈ A newly independent Indian CDMOMomentum neutral 58
Mkt cap
$1.95B
US dollars, full cap
Free float
52%
of shares outstanding
$/day
$15.1M
20-day average traded
Fwd P/E
44.6×
forward earnings
ROIC−WACC
-14.7 pp
WACC 15.8%
Hurdle
n/a
no reverse DCF
Next earnings
65 days
22 Jan 2027
Close · INR₹1,586
1D+0.3%
1W+0.3%
1M+16.1%
3M+2.9%
6M-14.5%
YTD-12.4%
1Y-9.8%
ATR %3.6%
Beta-0.15
52w lowhigh17.3% off high

What OneSource Specialty Pharma does

CDMO manufacturing complex injectables, ophthalmics and biologics for global pharma clients, spun off from Strides Pharma.

In one line: A newly independent Indian CDMO.

Products and services

  • Injectables CDMO
  • Ophthalmic manufacturing
  • Biologics/ADC manufacturing

Customers

  • Global pharma/biotech partners

Where it sits in the supply chain

  • CDMO manufacturing
  • Complex…
  • Global regulatory filings

What could go right

  • Global CDMO outsourcing growth
  • New client contract wins

What could go wrong

  • Client concentration post-spinoff
  • Regulatory inspection risk

Moat: narrow (regulatory licence, process know-how). Specialized regulated manufacturing facilities for complex dosage forms are costly for new entrants.

Headquarters: Bengaluru, India · Employees: 2,289

Named competitors

OneSource Specialty Pharma at a glance

Size OneSource Specialty Pharma (ONESOURCE.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.95B, the 382nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,586 on 18 Nov 2026.

Performance Over six months the shares fell 14.5%, against -1.3% for the median peer and +3.8% for the India market (cap-weighted) — 7th lowest of 21 in its peer set.

Growth Revenue grew 10.7% over the last twelve months (peer median +8.7%); the operating margin is 6.4% (peer median 20.9%).

Valuation It trades at 44.6× forward earnings against a peer median of 20.0× (4th most expensive of 17).

Capital Return on invested capital runs 14.7 points below its cost of capital (15.8% WACC).

Next results Next results expected around 22 Jan 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 97ONESOURCE.NS 85
Six months, rebased to 100: OneSource Specialty Pharma against the median of its 20 peers (local-currency closes).

OneSource Specialty Pharma financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹16.8B₹14.2B₹14.4B₹1.72B₹387M
Revenue growth—-2%+740%+344%—
Gross profit₹5.92B₹3.85B₹4.53B-₹1.94B-₹1.48B
EBITDA₹3.96B₹2.75B₹4.65B-₹1.98B-₹2.00B
Net income-₹16.2M-₹738M-₹180M-₹3.91B-₹8.00B
Free cash flown/a-₹6.80B-₹3.39B-₹2.71B-₹3.09B
Capital expendituren/a₹5.69B₹1.28B₹638M₹440M
Total debt₹17.5B₹15.0B₹9.42B₹5.71B₹8.64B

Quarterly statements and history in the cockpit →

OneSource Specialty Pharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%+20%BHVNHRMY60020145400512SHILPAMEDERISALIVUS9969009420PFIZER300009300436600211603456COHANCE603707600285000908DMPONESOURCE.NS6-month return →1-month return →
Up and to the right = strong over both horizons. OneSource Specialty Pharma is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%50×100×HRMY6002014540SHILPAMEDERISALIVUS9969PFIZER300009603456COHANCE603707ONESOURCE.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OneSource Specialty Pharma is the large dot.

OneSource Specialty Pharma competitors and peer comparison

Head to head with its named competitors (ONESOURCE.NS vs PPLPHARMA.NS vs SYNGENE.NS vs GLAND.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
OneSource Specialty Pharma ONESOURCE.NS$1.95B-14%+11%6%44.6×n/a
Piramal Pharma PPLPHARMA.NS$3.40B+38%+9%3%150.8×n/a
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%
Gland Pharma GLAND.NS$5.71B+44%+22%21%39.3×20.2%

How OneSource Specialty Pharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OneSource Specialty Pharma against its 20 peers (data as of 18 Nov 2026)
MeasureONESOURCE.NSPeer medianRank in peer set
1-month return+16.1%+0.3%3rd highest of 21
6-month return-14.5%-1.3%7th lowest of 21
Distance from 52-week high-17.3%-28.8%5th highest of 21
Revenue growth (TTM)+10.7%+8.7%10th highest of 20
Operating margin6.4%20.9%5th lowest of 20
Forward P/E44.6×20.0×4th most expensive of 17
ROIC minus cost of capital-14.7 pp+1.6 pp4th lowest of 20
EV / EBITDA50.3×15.0×2nd most expensive of 10
Net debt / EBITDA4.3×1.1×most indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Eris Lifesciences ERIS.NSIndia$1.98B0%+11%26%27.9×26.3%+20.9%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
InnoCare Pharma 9969.HKHong Kong$2.01B-10%+146%35%32.2×-2.0%+341.1%
Hanall Biopharma 009420.KSSouth Korea$2.01B+12%+5%3%n/an/an/a
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Fujian Cosunter Pharmaceutical 300436.SZChina$2.02B-45%0%-47%n/an/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Zhejiang Jiuzhou Pharmaceutical 603456.SSChina$2.03B+19%-1%14%16.9×1.7%+15.7%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Nanjing King-friend Biochemical Pharmaceutical 603707.SSChina$2.03B-3%+9%14%25.9×5.1%+6.4%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%15.9×-4.7%+10.6%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%

Questions

Who are OneSource Specialty Pharma's main competitors?
Named competitors: Piramal Pharma (PPLPHARMA.NS), Syngene International (SYNGENE.NS), Gland Pharma (GLAND.NS). The cockpit's measured peer set (industry) also includes Biohaven (BHVN), Harmony Biosciences (HRMY), Jinyu Bio-Technology (600201.SS), Tsumura & (4540.T), Grand Pharmaceutical (0512.HK), Shilpa Medicare (SHILPAMED.NS).
Is OneSource Specialty Pharma expensive compared with its peers?
On forward p/e it trades at 44.6× against a peer median of 20.0×, 4th most expensive of 17 in its peer set.
How has OneSource Specialty Pharma stock performed?
Over six months to 18 Nov 2026 the shares returned -14.5% against -1.3% for the median peer; over one year -9.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.